Revance CEO outlines sales force expansion to boost DAXXIFY growth
Moiz plans to expand Revance’s sales force and provider education to accelerate uptake of DAXXIFY, the first peptide-formulated neuromodulator, alongside SkinPen microneedling and RHA dynamic fillers. He aims to integrate aesthetics, therapeutics and skincare divisions under science-driven innovation to boost revenue growth.
1. Product Portfolio
Revance’s portfolio includes DAXXIFY, the first peptide-formulated neuromodulator for moderate to severe frown lines, SkinPen microneedling device, and RHA Collection hyaluronic acid fillers designed for dynamic movement, alongside consumer skincare lines such as PanOxyl and StriVectin.
2. CEO Vision and Strategy
Since his appointment on October 1, Nadeem Moiz has emphasized building a customer-centric, science-driven aesthetics and skincare company, unifying aesthetics, therapeutics and consumer skincare divisions to deliver innovative, authentic solutions and strengthen provider and patient partnerships.
3. Commercial Acceleration and Opportunities
Moiz identifies commercial acceleration as the primary growth lever, targeting expanded sales force deployment, enhanced provider and patient education, and deeper market penetration to realize DAXXIFY’s full potential and drive accelerated revenue growth across all divisions.